EXOZ net incomeQ2 2026-$2.88M
EXOZ net income was -$2.88M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.36M a year earlier. For the full fiscal 2025 it was -$9.16M, compared with -$5.86M in fiscal 2024.
eXoZymes Inc. (EXOZ) financials
For the twelve months ended Jun 30, 2026, eXoZymes Inc. reported -$10.19M of net income.
- Net income, TTM
- -$10.19M
- Free cash flow, TTM
- -$7.14M
- EPS, diluted, TTM
- -$1.20
- Cash
- $5.65M
- Market cap
- $39.8M
FY2023FY2025
FY2023FY2025
EXOZ revenue and earnings growth
EXOZ EPSQ2 2026-$0.33
EXOZ diluted EPS was -$0.33 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.28 a year earlier. For the full fiscal 2025 it was -$1.09, compared with -$0.89 in fiscal 2024.
EXOZ free cash flowQ2 2026-$1.64M
EXOZ free cash flow was -$1.64M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.59M a year earlier. For the full fiscal 2025 it was -$6.67M, compared with -$8.90M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Revenue | - | - | $70.1K |
| Research and development | $3.71M | $1.87M | $527.5K |
| Selling, general and admin | $6.01M | $4.06M | $1.34M |
| Operating income | -$9.72M | -$5.93M | -$1.80M |
| Pre-tax income | -$9.26M | -$5.86M | -$2.00M |
| Income tax | -$105.2K | - | $42.3K |
| Net income | -$9.16M | -$5.86M | -$2.04M |
| EPS, basic | -$1.09 | -$0.89 | -$0.33 |
| EPS, diluted | -$1.09 | -$0.89 | -$0.33 |
| Diluted shares | 8.4M | 6.6M | 6.3M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $3.04M | $9.72M | $66.5K |
| Current assets | $3.94M | $10.82M | $1.21M |
| Total assets | $5.97M | $13.03M | $3.56M |
| Current liabilities | $1.57M | $1.33M | $2.42M |
| Total liabilities | $2.57M | $2.61M | $3.94M |
| Shareholders' equity | $3.40M | $10.42M | -$384.3K |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$6.50M | -$8.51M | -$1.18M |
| Capital expenditures | $169.9K | $396.5K | $288.7K |
| Free cash flow | -$6.67M | -$8.90M | -$1.47M |
| Investing cash flow | -$150.2K | -$359.2K | -$311.2K |
| Financing cash flow | -$27.7K | $18.52M | $1.00M |
| Stock-based compensation | $1.99M | $1.13M | $281.5K |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | -$700 | - |
| Research and development | $1.44M | $1.12M | $1.11M | $1.22M | $803.0K | $575.0K | $630.3K | $723.5K | $237.4K | $277.6K | $460.4K | $27.9K |
| Selling, general and admin | $1.52M | $1.27M | $1.58M | $1.31M | $1.75M | $1.38M | $1.35M | $888.2K | $1.09M | $730.9K | $524.0K | $363.9K |
| Operating income | -$2.95M | -$2.39M | -$2.70M | -$2.52M | -$2.55M | -$1.95M | -$1.98M | -$1.61M | -$1.33M | -$1.01M | -$985.0K | -$391.8K |
| Interest expense | - | - | - | - | - | - | - | $44.6K | - | - | - | - |
| Pre-tax income | -$2.88M | -$2.37M | -$2.76M | -$2.29M | -$2.36M | -$1.86M | -$1.84M | -$1.66M | -$1.36M | -$1.01M | -$1.06M | -$520.6K |
| Income tax | - | - | - | - | - | - | - | -$1 | $2.1K | $0 | - | - |
| Net income | -$2.88M | -$2.37M | -$2.66M | -$2.29M | -$2.36M | -$1.86M | -$1.84M | -$1.66M | -$1.36M | -$1.01M | -$1.10M | -$520.6K |
| EPS, basic | -$0.33 | -$0.28 | -$0.32 | -$0.27 | -$0.28 | -$0.22 | -$0.24 | -$0.27 | -$0.22 | -$0.16 | - | -$0.08 |
| EPS, diluted | -$0.33 | -$0.28 | -$0.32 | -$0.27 | -$0.28 | -$0.22 | -$0.24 | -$0.27 | -$0.22 | -$0.16 | - | -$0.08 |
| Diluted shares | 8.7M | 8.5M | - | 8.4M | 8.4M | 8.4M | - | 6.3M | 6.3M | 6.3M | - | 6.3M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.65M | $1.44M | $3.04M | $5.10M | $6.99M | $8.51M | $9.72M | $233.9K | $158.2K | $113.8K | $66.5K | $474.6K |
| Current assets | $6.17M | $2.09M | $3.94M | $5.61M | $7.53M | $9.42M | $10.82M | $1.42M | - | - | $1.21M | - |
| Total assets | $7.98M | $4.02M | $5.97M | $7.72M | $9.68M | $11.53M | $13.03M | $3.56M | - | - | $3.56M | - |
| Current liabilities | $1.62M | $1.58M | $1.57M | $1.24M | $1.22M | $1.44M | $1.33M | $5.80M | - | - | $2.42M | - |
| Total liabilities | $4.33M | $2.49M | $2.57M | $2.34M | $2.44M | $2.64M | $2.61M | $7.16M | - | - | $3.94M | - |
| Shareholders' equity | $3.65M | $1.53M | $3.40M | $5.37M | $7.24M | $8.88M | $10.42M | -$3.60M | -$2.26M | -$1.25M | -$384.3K | $607.1K |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.64M | -$1.52M | -$1.97M | -$1.86M | -$1.54M | -$1.13M | -$5.71M | -$541.5K | -$2.54M | $281.2K | -$783.3K | - |
| Capital expenditures | -$1 | $57.6K | $75.0K | $13.3K | $50.6K | $31.0K | $210.4K | $0 | $37.2K | $148.8K | $109.7K | - |
| Free cash flow | -$1.64M | -$1.58M | -$2.05M | -$1.87M | -$1.59M | -$1.16M | -$5.92M | -$541.5K | -$2.58M | $132.4K | -$893.0K | - |
| Investing cash flow | $1 | -$57.6K | -$75.0K | -$13.3K | -$30.9K | -$31.0K | -$210.4K | $30.9K | -$37.2K | -$142.4K | -$109.7K | - |
| Financing cash flow | $5.85M | -$12.7K | -$10.6K | - | - | -$43.3K | $15.40M | $586.4K | $2.62M | -$91.5K | $485.0K | - |
| Stock-based compensation | $1.22M | $501.1K | $677.9K | $425.7K | $567.3K | $317.3K | $317.3K | $317.3K | $348.3K | $142.8K | $107.1K | - |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 3.81 | 1.32 | 2.51 | 4.53 | 6.19 | 6.52 | 8.12 | 0.25 | - | - | 0.50 | - |
Source: XBRL data eXoZymes Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
EXOZ peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| EXOZ | - | - | -$10.19M | - | $39.8M |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
EXOZ FAQ
6 questionsIs EXOZ profitable?
No. eXoZymes Inc. reported a net loss of $10.19M for the twelve months ended Jun 30, 2026.How much cash and debt does EXOZ have?
eXoZymes Inc. reported $5.65M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is EXOZ free cash flow?
eXoZymes Inc. generated -$7.14M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$7.00M less capital expenditures.What is EXOZ earnings per share?
Diluted earnings per share were -$1.20 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did EXOZ last report financial results?
The latest statements here come from eXoZymes Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this EXOZ financial data come from?
Quantisnow builds these statements from the structured XBRL data eXoZymes Inc. files with the SEC. It is provided for information only and is not investment advice.